PharmTech Drug Digest 11.20
News|Articles|July 5, 2017

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-08-02-2017
  • Volume 12
  • Issue 8

Samsung BioLogics to Manufacture Tildrakizumab

Samsung BioLogics signs $55.5 million agreement to manufacture tildrakizumab for Sun Pharma.

Sun Pharma and Samsung BioLogics announced on July 4, 2017 a strategic long-term manufacturing agreement that Samsung Biologics will manufacture tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis. The approximate value of the contract will be $55.5 million, the companies reported in a press announcement.

Filings for the novel investigational biologic was accepted for review by FDA in May 2017) and the European Medicines Agency in March 2017.

“Samsung BioLogics is pleased to join hands with Sun Pharma and is looking forward to delivering best-in-class manufacturing services with global quality standards,” said TH Kim, President and CEO of Samsung BioLogics in the statement. “Our collaboration with Sun Pharma is an important milestone for Samsung as it is a testament of our ability to provide reliable supply through its GMP-certified manufacturing facility to pharmaceutical companies, which aim to expand their global market.”

“Samsung BioLogics is a globally renowned CMO. Through this partnership we will leverage Samsung’s manufacturing knowledge and world class quality systems to provide high quality products for the tildrakizumab pipeline,” said Kirti Ganorkar, Global Head – Portfolio Management & Business Development, Sun Pharma.

Source: Samsung Biologics

 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.